title: Therapeutic effect of recombinant plasmid-encoded human interleukin-12             in tumor-bearing mice.
abstract: The aim of this study was to investigate the effects of gene therapy using             a recombinant plasmid encoding human interleukin-12 (rIL-12, pcDNA6-p70) on transplanted             tumors in mice. Tumor-bearing mice were transplanted with sarcoma‑180 (S-180)             cells and randomly divided into three groups of 10 mice with each group receiving             a separate treatment. Following this, pcDNA6-p70 (dissolved in purified water;             100 µg/mouse), cyclophosphamide (dissolved in 0.9% saline; 40 mg/kg) or 0.9% saline             (100 µl/mouse) was directly injected into the tumors on the 4th, 7th, 10th, 14th             and 17th days following transplantation of the S-180 cells. Mice survival time             was monitored and surviving mice were sacrificed on the 21st day. In addition             to survival time, tumor volume, NK cell activity, spleen lymphocyte proliferation             and IFN-γ production were investigated. The mice were also monitored for any adverse             effects regarding the administration of pcDNA6-p70. Our results demonstrated that             pcDNA6-p70 prolongs the survival time of tumor-bearing mice, decreases tumor size             (P<0.01) and increases the proliferative response of spleen cells, the activity             of NK cells and the serum level of IFN-γ. There were no significant adverse effects             caused by the administration of pcDNA6-p70. The results of the present study support             the hypothesis that gene therapy using the rIL-12 plasmid exerts a therapeutic             effect in tumor models by triggering antitumor cellular immunity.
authors: Department of Microbiology, Shandong Medical College, Linyi, Shandong 276002, PR China. sunyunfangsd@126.com
authors: Yunfang
authors: Y
authors: Sun
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004195:Disease Models, Animal; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000378:metabolism; D018664:Interleukin-12 / Q000235:genetics / Q000378:metabolism*; D007694:Killer Cells, Natural / Q000166:cytology / Q000276:immunology; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D010957:Plasmids / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D013154:Spleen / Q000166:cytology / Q000276:immunology; D014184:Transplantation, Homologous
chemical_list: D011994:Recombinant Proteins; D018664:Interleukin-12; D007371:Interferon-gamma